Abstract
We describe a 63-year-old woman with a diagnosis of breast cancer who relapsed with multiple bone lesions 18 years later. The biological characteristics were estrogen receptor positive, progesterone receptor positive, and HER2-positive cancer. Lapatinib and letrozole was the treatment of choice as a manageable and active first-line therapy for this patient.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Biomarkers, Tumor / blood*
-
Bone Nails
-
Bone Neoplasms / chemistry
-
Bone Neoplasms / complications
-
Bone Neoplasms / diagnosis
-
Bone Neoplasms / drug therapy*
-
Bone Neoplasms / secondary*
-
Breast Neoplasms / drug therapy
-
Breast Neoplasms / pathology*
-
Carcinoma, Ductal, Breast / drug therapy*
-
Carcinoma, Ductal, Breast / secondary*
-
Female
-
Femoral Fractures / prevention & control
-
Humans
-
Ki-67 Antigen / blood
-
Lapatinib
-
Letrozole
-
Magnetic Resonance Imaging
-
Middle Aged
-
Neoplasm Staging
-
Nitriles / administration & dosage
-
Pain / etiology
-
Pain Management
-
Quinazolines / administration & dosage
-
Receptor, ErbB-2 / analysis
-
Receptors, Estrogen / blood
-
Receptors, Progesterone / blood
-
Treatment Outcome
-
Triazoles / administration & dosage
Substances
-
Biomarkers, Tumor
-
Ki-67 Antigen
-
Nitriles
-
Quinazolines
-
Receptors, Estrogen
-
Receptors, Progesterone
-
Triazoles
-
Lapatinib
-
Letrozole
-
ERBB2 protein, human
-
Receptor, ErbB-2